News
Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
6d
Zacks Investment Research on MSNAmgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.
These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...
Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...
What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient reten ...
3d
The Print on MSNIndia sees 20k bariatric surgeries a year. But blockbusters Mounjaro, Wegovy are shaking up obesity arena
India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results